Hematología y Hemoterapia

Resultados: 385
Tipo Título / Nombre Autor(es) Año
Treatment Outcomes in Unfit Patients with Newly Acute Myeloid Leukemia According to IDH1 Mutational Status: Real World Evidence from the Pethema Epidemiologic Registry Martínez-Cuadron D, Boluda B, Lorenzo Algarra J..., Bergua Burgues JM 2023
Clinical Features and Treatment in Patients Diagnosedwith Blastic Plasmacytoid Dendritic Cell Neoplasm: Interim Analysis from the Pethema EpidemiologicRegistry (EPI-BLAS study) Navarro Vicente I, Lloret Madrid P. Solana-Altabella A..., Bergua Burgues JM 2023
Patients with Paroxysmal Nocturnal Hemoglobinuria (PNH) Treated with Pegcetacoplan: Real Life Experience Vallejo C, Bonanad Boix S, Carnicero F, Gaya A, González AP, González Fernández FA, et al 2023
A High Percentage of DNAM-1+ and Low Percentage of Tactile+ NK Cells at Diagnosis Correlate with Complete Response and Survival in AML: A Sub-Analysis of the Ven-a-Qui Pethema Trial Bergua Burgues JM, Tarazona R, García Casado J, Gordillo JJ, Casas Aviles I, Rodríguez Veiga R, et al 2023
Mosunetuzumab and Polatuzumab Vedotin Demonstrates Preliminary Efficacy in Elderly Unfit/Frail Patients with Previously Untreated Diffuse Large B-Cell Lymphoma Olszewski AJ, Eradat H, Avigdor A, Horowitz NA..., Bergua Burgues JM 2023
FOVOCIP study: a multicenter randomized trial of fosfomycin versus ciprofloxacin for febrile neutropenia in hematologic patients-efficacy and microbiologic safety Moreno AF, Lavín-Alconero L, de Ugarriza PL, Blanco LS, Hernández SC, Burgués JMB, et al 2023
COVALENT-101: phase I study of BMF-219, a covalent menin inhibitor, in adult patients with AML, ALL (with KMT2A/ MLL1r, NPM1 mutations), DLBCL, MM, and CLL/SLL (NCT05153330) Rosenberg A, Baljevic M, Alegre Amor A..., Bergua Burgues JM 2023
COVALENT-101: Phase I Study of BMF-219, a Covalent Menin Inhibitor, in Adult Patients With AML, ALL (With KMT2A/MLL1 Rearrangements, NPM1 Mutation), DLBCL, MM, and CLL/SLL (NCT05153330) Ravandi F, Lancet J..., Bergua Burgues JM 2023
Mezigdomide plus Dexamethasone in Relapsed and Refractory Multiple Myeloma Richardson PG, Trudel S, Popat R, Mateos MV, Vangsted AJ..., Casas Avilés I, et al 2023
Feasibility and outcomes after dose reduction of immunochemotherapy in young adults with Burkitt lymphoma and leukemia: results of the BURKIMAB14 trial Ribera JM, Morgades M, Garcia-Calduch O, Sirvent M, Buendia B..., Bergua JM, et al 2023